what’s new with kasper a lot! facilitator: dr. michelle lofwall, uk associate professor of...

9
What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van Ingram, Executive Director, Kentucky Office of Drug Control Policy Dr. Ryan Stanton, Medical Director ER, UK Good Samaritan Hospital

Upload: cecily-walton

Post on 05-Jan-2016

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

What’s New with KASPER

A Lot!

Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry

Panelists:Dave Hopkins, KASPER Program ManagerVan Ingram, Executive Director, Kentucky Office of Drug Control PolicyDr. Ryan Stanton, Medical Director ER, UK Good Samaritan Hospital

Page 2: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Controlled Substances Dispensed

Cabinet for Health and Family Services

2006 2007 2008 2009 2010 2011 2012

93143401005992910273400

11124085114091401173057411167214

Nu

mb

er

of

Re

co

rds

Page 3: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

KASPER Reports Requested

Cabinet for Health and Family Services

2006 2007 2008 2009 2010 2011 2012

186 274 362 418

708 811

2,691

Nu

mb

er

of

Re

po

rts

in T

ho

us

an

ds

Page 4: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Cabinet for Health and Family Services

Top Prescribed Controlled Substances byTherapeutic Category by Doses - 2012

Hydrocodone 41.5% LortabLorcetVicodin

Alprazolam 11.8%Xanax

Tramadol 6.9%Ultram

Oxycodone 15.9% OxyContinPercodanPercocet

Clonazepam 6.6%Klonopin

Diazepam 4.5%Valium

Phentermine 2.4%

Adipex-P

Amphetamine 2.7%

Adderall

Zolpidem 3.5%Ambien

Lorazepam 4.0%Ativan

Page 5: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Cabinet for Health and Family Services

KASPER Stakeholders• Licensing Boards – to investigate potential inappropriate

prescribing by a licensee. • Practitioners and Pharmacists – to review a current

patient’s controlled substance prescription history for medical and/or pharmaceutical treatment.

• Law Enforcement Officers, OIG employees, Commonwealth’s attorneys, county attorneys - to review an individual’s controlled substance prescription history as part of a bona fide drug investigation or drug prosecution.

• Medicaid – to screen members for potential abuse of pharmacy benefits and to determine “lock-in”; to screen providers for adherence to prescribing guidelines for Medicaid patients.

• A judge or probation or parole officer – to help ensure adherence to drug diversion or probation program guidelines.

Page 6: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Cabinet for Health and Family Services

KASPER Usage 2012

Law Enforcement = .4%(17% of KY LE have

accounts)

Prescribers = 97.9%(83% of KY prescribers have accounts)

Pharmacists = 1.6%(83% of KY

pharmacists have accounts)

Judges, Other= .1%

Page 7: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Cabinet for Health and Family Services

eKASPER Master Accounts

12/31/2011 04/24/2012 07/20/2012 12/31/2012

Doctor* 5,470       5,680     11,923     16,740

APRN 690          781       1,523       1,866

Pharmacist 1,385       1,450       3,602       4,888

Total 7,545       7,911     17,048     23,494

*Includes physicians, dentists, optometrists and podiatrists

Page 8: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

Cabinet for Health and Family Services

HB1 Early Results

Drug Aug-Nov 2011 Aug-Nov 2012 ChangeHydrocodone 81,125,721 71,372,106 -12.0%

Oxycodone 29,768,546 26,256,240 -11.8%

Oxymorphone 679,621 380,353 - 44.0%

Alprazolam 24,877,998 21,277,555 -14.5%

Methylphenidate 3,551,129 3,722,988 + 4.8%

Amphetamine 4,528,805 4,873,753 + 7.6%

All Controlled Substances 251,848,764 222,487,691 -11.7%

Figures shown in doses dispensed

Page 9: What’s New with KASPER A Lot! Facilitator: Dr. Michelle Lofwall, UK Associate Professor of Psychiatry Panelists: Dave Hopkins, KASPER Program Manager Van

KASPER Web Site: www.chfs.ky.gov/KASPER